AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HELLENIC DYNAMICS PLC

Report Publication Announcement Nov 23, 2023

5118_rns_2023-11-23_9f519c1b-48a5-4c12-b89e-5cbfb8c53697.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3918U

Hellenic Dynamics PLC

23 November 2023

23 November 2023

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

New Company Presentation and Facility Presentation

London, 23 November 2023, Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the fast growing European medical cannabis markets announces the publication of its new company presentation and accompanying facility presentation.

Company Presentation

Hellenic is pleased to provide its updated company presentation which can be accessed via the link 'Company Presentation' and will be available on the Company's website by end of today.

Facility Presentation

Further to the announcement made on 10 October 2023, Hellenic is pleased to provide its new facility presentation via the following link 'Facility Presentation' and will be available on the Company's website by end of today.

Enquires: 

Hellenic Dynamics plc +44 (0) 20 3818 7850
Davinder Rai [email protected]
Peterhouse Capital +44 (0)20 7469 0930
Lucy Williams / Charles Goodfellow

About Hellenic Dynamics plc

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

26 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach $17.39 billion per annum by 2028. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 24 other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

For further information please visit our website www.hellenicdynamics.com  

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGZMZMMZVGFZZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.